Page last updated: 2024-08-24

irinotecan and Lymphoma, Large B-Cell, Diffuse

irinotecan has been researched along with Lymphoma, Large B-Cell, Diffuse in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's6 (75.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S1
Barker, JN; Gupta, NK; Noy, A; Young, JW1
Kirschbaum, M1
Fukushima, T; Hirose, Y; Karasawa, H; Kawabata, H; Kawanami, T; Masaki, Y; Ogawa, N; Sawaki, T; Shimoyama, K; Sugai, S; Umehara, H; Wano, Y1
Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N1
Kang, HJ; Kim, BS; Kim, WS; Park, YH; Ryoo, BY; Suh, C; Yuh, YJ1
Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N1
Asai, J; Fujimoto, T; Miyo, T; Nagashima, G; Suzuki, R1

Trials

2 trial(s) available for irinotecan and Lymphoma, Large B-Cell, Diffuse

ArticleYear
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
    Cancer science, 2006, Volume: 97, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T

2006
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Rituximab; Salvage Therapy; Vincristine

2008

Other Studies

6 other study(ies) available for irinotecan and Lymphoma, Large B-Cell, Diffuse

ArticleYear
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
    Annals of hematology, 2015, Volume: 94, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome

2015
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2009
Comeback for the camptothecins?
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2009
[Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Remission Induction; Salvage Therapy; Treatment Outcome

2005
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
    International journal of hematology, 1999, Volume: 69, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy

1999
[Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cerebellar Neoplasms; Cranial Irradiation; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local

2000